Supplementary Table 6. Multivariable analysis of body composition measures stratified by treatment group

Response	OR	95% CI	p-value
Total cohort			
SMG (High vs Low)	0.90	0.36-2.28	0.83
TATI (Medium vs Low)	1.24	0.48-3.22	0.66
TATI (High vs Low)	0.39	0.15-1.02	0.06
Combination Therapy			
SMG (High vs Low)	0.89	0.07-11.1	0.93
TATI (Medium vs Low)	0.47	0.04-5.88	0.56
TATI (High vs Low)	0.95	0.07-12.70	0.97
Monotherapy			
SMG (High vs Low)	0.84	0.29-2.39	0.74
TATI (Medium vs Low)	1.61	0.55-4.69	0.38
TATI (High vs Low)	**0.3**	**0.10-0.90**	**0.032**
Total cohort			
SMG (High vs Low)	1.21	0.70-2.10	0.48
TATI (Medium vs Low)	1.07	0.61-1.90	0.81
TATI (High vs Low)	**1.71**	**1.01-2.87**	**0.04**
Combination Therapy			
SMG (High vs Low)	1.39	0.29-6.75	0.68
TATI (Medium vs Low)	2.44	0.55-10.72	0.24
TATI (High vs Low)	0.78	0.14-4.20	0.77
Monotherapy			
SMG (High vs Low)	1.23	0.68-2.22	0.5
TATI (Medium vs Low)	0.9	0.47-1.71	0.74
TATI (High vs Low)	**2.01**	**1.14-3.55**	**0.016**
OS	**HR**	**95% CI**	**p-value**
Total Cohort			
SMG (High vs Low)	0.99	0.53-1.83	0.97
TATI (Medium vs Low)	1.18	0.61-2.26	0.62
TATI (High vs Low)	1.44	0.80-2.61	0.22
Combination Therapy			
SMG (High vs Low)	2.18	0.34-13.98	0.41
TATI (Medium vs Low)	2.73	0.43-17.21	0.28
TATI (High vs Low)	1.08	0.15-7.98	0.94
Monotherapy			

SMG (High vs Low)	0.81	0.42-1.58	0.54
TATI (Medium vs Low)	1.04	0.51-2.12	0.91
TATI (High vs Low)	1.43	0.76-2.70	0.27

P-values ≦0.05 displayed in bold.

Adjusted for age, sex, stage, prior treatment and SMG:TATI interaction term